StoxGlenmark Pharmaceuticals vs Aster DM Quality Care: share price & financials comparison
NSE: GLENMARK vs ASTERDM · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glenmark Pharmaceuticals vs Aster DM Quality Care at a glance
Glenmark Pharmaceuticals (GLENMARK) has a market capitalisation of ₹74,506 Cr, against ₹62,979 Cr for Aster DM Quality Care (ASTERDM). Over the past year Glenmark Pharmaceuticals has returned +43.1%, compared with +4.9% for Aster DM Quality Care. On valuation, Glenmark Pharmaceuticals trades at a lower P/E of 84.1 versus 133.8. Glenmark Pharmaceuticals earns a higher return on equity (7.9% vs 6.0%). Glenmark Pharmaceuticals comes out ahead on valuation, financial health, momentum and technicals. Aster DM Quality Care comes out ahead on size, profitability and growth. Across the scored metrics below, Glenmark Pharmaceuticals leads on 12 and Aster DM Quality Care on 5. On StoxGud's 10-point checklist, Glenmark Pharmaceuticals scores 5/10 and Aster DM Quality Care scores 5/10.
| Metric | Glenmark Pharmaceuticals | Aster DM Quality Care |
|---|---|---|
| Size | ||
| Market cap | ₹74,506 Cr | ₹62,979 Cr |
| Revenue (latest FY) | ₹16,983 Cr | ₹4,643 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹388 Cr |
| Valuation | ||
| P/E | 84.1 | 133.8 |
| P/B | 6.64 | 8.08 |
| Dividend yield | 0.19% | 0.09% |
| Profitability | ||
| Return on equity | 7.9% | 6.0% |
| Net profit margin | 5.6% | 7.2% |
| Operating margin | 20.3% | 21.1% |
| Growth | ||
| Revenue growth (YoY) | -31.3% | +136.3% |
| Net profit growth (YoY) | -100.0% | +138.2% |
| Revenue CAGR (multi-year) | +9.2% | -11.6% |
| Financial health | ||
| Debt to equity | 0.08 | 0.51 |
| Momentum | ||
| 1-month return | +16.5% | +4.7% |
| 1-year return | +43.1% | +4.9% |
| 3-year CAGR | +53.9% | +28.3% |
| 5-year CAGR | +37.6% | +28.4% |
| 10-year CAGR | +11.7% | — |
| Distance from 52W high | -1.4% | -16.9% |
| Technicals | ||
| RSI (14) | 85 | 76 |
| Price vs 200-day avg | +17.4% | +0.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glenmark Pharmaceuticals | Aster DM Quality Care |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 5/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glenmark Pharmaceuticals or Aster DM Quality Care?
Glenmark Pharmaceuticals has a market cap of ₹74,506 Cr and Aster DM Quality Care has a market cap of ₹62,979 Cr as of 13 Nov 2026.
Which has a lower P/E, Glenmark Pharmaceuticals or Aster DM Quality Care?
Glenmark Pharmaceuticals has the lower P/E: Glenmark Pharmaceuticals trades at 84.1 and Aster DM Quality Care at 133.8.
Which gave better returns in the last year, Glenmark Pharmaceuticals or Aster DM Quality Care?
Glenmark Pharmaceuticals did better: Glenmark Pharmaceuticals returned +43.1% and Aster DM Quality Care returned +4.9% over one year.
What is the difference between Glenmark Pharmaceuticals and Aster DM Quality Care?
Both are NSE-listed companies in Healthcare. Glenmark Pharmaceuticals is about 1.2 times the size of Aster DM Quality Care by market cap. In the latest financial year Glenmark Pharmaceuticals reported revenue of ₹16,983 Cr and Aster DM Quality Care ₹4,643 Cr. Operating margin is 20.3% for Glenmark Pharmaceuticals and 21.1% for Aster DM Quality Care. Debt to equity is 0.08 for Glenmark Pharmaceuticals and 0.51 for Aster DM Quality Care.
Which is better, Glenmark Pharmaceuticals or Aster DM Quality Care?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Glenmark Pharmaceuticals leads on 12 and Aster DM Quality Care on 5. Glenmark Pharmaceuticals is ahead on valuation, financial health, momentum and technicals. Aster DM Quality Care is ahead on size, profitability and growth. On StoxGud's rules-based checklist Glenmark Pharmaceuticals scores 5/10 and Aster DM Quality Care scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.